MBX-8025 2 mg Capsule + MBX-8025 5 mg Capsule + MBX-8025 10 mg Capsule
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Biliary Cirrhosis
Conditions
Primary Biliary Cirrhosis
Trial Timeline
Nov 28, 2016 → Jul 8, 2019
NCT ID
NCT02955602About MBX-8025 2 mg Capsule + MBX-8025 5 mg Capsule + MBX-8025 10 mg Capsule
MBX-8025 2 mg Capsule + MBX-8025 5 mg Capsule + MBX-8025 10 mg Capsule is a phase 2 stage product being developed by Gilead Sciences for Primary Biliary Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02955602. Target conditions include Primary Biliary Cirrhosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02955602 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Biliary Cirrhosis